Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: 4 - Caught on Camera

Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

MarketBeat

US stocks today: S&P 500 and Nasdaq hit record closing highs as US and Iran agree to extend ceasefire

The S&P 500 and Nasdaq hit record closing highs as hopes of a US Iran ceasefire extension boosted sentiment. Investors also digested US inflation rising to a three-year high and weaker GDP revision. AI and tech stocks led gains, with Microsoft, Snowflake, Eli Lilly and Marvell among top movers today.

The Economic Times

Is Eli Lilly Stock Outperforming the Nasdaq?

Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

The $4 Billion Reason Eli Lilly Stock Is Up Today

Eli Lilly shares inch higher as the company announced three acquisitions for nearly $4 billion. Here’s why each of the three vaccine makers it’s buying is bullish for LLY stock.

Barchart

Is the End of the Obesity Epidemic Near? People Lost Up to 85 Pounds Using New Weight Loss Drug

Eli Lilly's retatrutide is a significant advance on the promising results from drugs like Ozempic and Wegovy.

Reason

New weight-loss shot appears to outperform other obesity drugs on market

Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugs

The Guardian - US

Super Ozempic? New weight-loss drug sees even better results in recent study

Many of the patients who tested the drug lost about 30 percent of their body weight — a loss comparable to the result of bariatric surgery

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

MarketBeat

Eli Lilly shares bought on Trump’s behalf as his policies benefited drug firm

Filings reveal $220m to $750m in trades on US president’s behalf in first quarter of 2026, including securities linked to largest US companies

The Guardian - US

This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Barchart

Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The campaign aimed to reframe obesity as a chronic disease. It featured various media without naming specific products. Lilly cited regulatory uncertainty and conflicting guidance. The regulator's advisory prohibited indirect promotion…

The Economic Times

What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

MarketBeat

Do Wall Street Analysts Like Eli Lilly Stock?

While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Wegovy maker Novo Nordisk boosted by successful weight loss pill launch

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

MarketBeat

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

Barchart

Eli Lilly Stock Popped on Earnings. America Can’t Get Enough of Its GLP-1s.

Eli Lilly stock jumps on strong Q1 performance numbers, with its GLP-1s leading the chart.

Barchart

GLP-1 Sales Continue to Lift Eli Lilly. Does That Make LLY Stock a Buy?

Eli Lilly stock rallies as GLP-1 sales drive a 56% year-on-year increase in Q1 revenue. Jim Cramer recommends buying LLY shares as the weight-loss addressable market is truly huge.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Should You Buy the Dip in Eli Lilly Stock Today?

Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today.

International Business Times

Eli Lilly and Co Reportedly Close to $2 Billion Acquisition of Kelonia Therapeutics

Eli Lilly is reportedly nearing a $2 billion deal to acquire Kelonia Therapeutics, aiming to expand its cancer treatment portfolio with next-generation therapies.

Axios

Indiana, Eli Lilly to partner to bring nuclear power to the state

Nuclear is seen as key to AI energy needs, but it's years away from large-scale viability.

The Times of India

UAE introduces first-ever weight loss pill Foundayo, here’s how much it may cost and where to get it

The UAE has approved Foundayo (orforglipron), Eli Lilly's once-daily oral obesity pill, becoming one of the first countries globally to offer a needle-free alternative. This GLP-1 receptor agonist mimics natural hormones to regulate appetite and blood sugar, aiding weight loss and improving metabolic health. Available by prescription from May 2026,…

The Independent UK

FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be linked to liver, heart and gastrointestinal problems

Barchart

The Next Big AI Winner Might Not Be a Tech Company

Lilly’s AI push shows how non-tech firms can dominate the next wave.

The Independent UK

Trump sets 100% tariffs on prescription drugs from companies that have not reached a deal with him to lower prices

The tariffs were announced on the anniversary of Trump’s ‘Liberation Day,’ which saw U.S. trading partners hit with sweeping levies

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.